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Summary 31 
Heparan sulfate proteoglycans (HSPGs) critically modulate adhesion-, growth- and migration-32 
related processes. Here we show that the transmembrane protein Nogo-A inhibits neurite 33 
outgrowth and cell spreading in neurons and Nogo-A-responsive cell lines via HSPGs. The 34 
extracellular, active, 180 aa Nogo-A region called Nogo-A-20 binds to heparin and brain-35 
derived heparan sulfate glycosaminoglycans (GAGs) but not to the closely related chondroitin 36 
sulfate GAGs. HSPGs are required for Nogo-A-20-induced inhibition of adhesion, cell 37 
spreading, neurite outgrowth as well as for RhoA activation. Surprisingly, we show that 38 
Nogo-A-20 can act via HSPGs independently of its receptor Sphingosine-1-Phosphate 39 
receptor 2 (S1PR2). We thereby identify a new functional binding receptor for Nogo-A-20 40 
and show that syndecan-3 and syndecan-4 are responsible for Nogo-A-20-induced effects. 41 
Finally, we show in explant cultures ex vivo that Nogo-A-20 promotes the migration of 42 
neuroblasts via HSPGs but not S1PR2.  43 
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Introduction 47 
Cell surface heparan sulfate proteoglycans (HSPGs) are highly expressed in the mammalian 48 
nervous system (Sarrazin et al., 2011; Yamaguchi, 2001). HSPGs regulate various 49 
developmental processes ranging from neuroblast migration, axon growth and guidance to 50 
synapse formation and neuronal connectivity (Inatani et al., 2003; Van Vactor et al., 2006; 51 
Yamaguchi, 2001). HSPGs transduce signals originating in the extracellular matrix (ECM) or 52 
act as obligate co-receptors for several morphogens, growth factors and axon guidance 53 
molecules (Bernfield et al., 1999; Sarrazin et al., 2011). Most studies on HSPGs have focused 54 
on the regulation of survival-, proliferation- or growth-promoting cues, e.g., fibroblast growth 55 
factor (FGF) (Sarrazin et al., 2011), rather than growth-inhibiting and repulsive factors. To 56 
our knowledge, only the repulsive activities of EphrinA3, Slit2 and S1P have been reported to 57 
critically depend on the presence of cell surface HSPGs so far (Hu, 2001; Irie et al., 2008; 58 
Strochlic et al., 2008). 59 
 60 
Nogo-A is a major anti-adhesive and neurite growth-inhibitory protein initially discovered for 61 
its role as myelin-associated inhibitor of axonal regeneration in the adult central nervous 62 
system (CNS) (Schwab, 2010). In addition to its role in the injured CNS, Nogo-A has been 63 
shown to regulate various developmental and plastic processes ranging from synapse 64 
formation to neuronal migration (Kempf and Schwab, 2013; Schwab and Strittmatter, 2014). 65 
In the adult brain, Nogo-A promotes cell motility and the tangential migration of neuroblasts 66 
along the rostral migratory stream (RMS) by triggering cell-cell repulsion (Rolando et al., 67 
2012). At hippocampal and cortical synapses, Nogo-A acts as a negative regulator of long 68 
term potentiation and memory stability (Karlsson et al., 2016; Schwab and Strittmatter, 2014). 69 
However, it is not known whether Nogo-A-evoked cellular responses are modulated by 70 
HSPGs. 71 
 72 
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In this study, we identified HSPGs as novel functional receptors for the active Nogo-A 73 
domain Nogo-A-20 (rat amino acid (aa) 544-725 (Oertle et al., 2003)). We found that Nogo-74 
A-20 activates RhoA and inhibits cell spreading and neurite outgrowth via HSPGs, 75 
specifically via the transmembrane HSPGs syndecan-4 and syndecan-3. In addition, we show 76 
that Nogo-A-20 inhibits cell adhesion of neuroblasts in an HSPG-dependent manner and 77 
increases neuroblast chain migration ex vivo. Our results propose a novel mechanism by 78 
which Nogo-A-20 affects cytoskeletal dynamics by interacting with HSPGs independently 79 
of the newly characterized Nogo-A-20 receptor Sphingosine-1-Phosphate receptor 2 80 
(S1PR2) (Kempf et al., 2014). 81 
  82 
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Results 83 
Cell surface heparan sulfate is required for Nogo-A-20-induced inhibition of cell 84 
spreading 85 
Outgrowth of neurites and spreading of cells, e.g. fibroblasts, are strongly inhibited by 86 
substrates containing Nogo-A or its active fragment Nogo-A-20 (Oertle et al., 2003) (Figure 87 
1A). To determine a possible role of heparan sulfate (HS), cell spreading inhibition was 88 
examined upon enzymatic cleavage of HS. Treatment of Swiss 3T3 cells with heparinase III 89 
(HepIII) significantly increased cell spreading by ~45% on the Nogo-A-20-coated culture 90 
dishes when compared to the vehicle (saline) control (Figure 1A,B). Treatment with 91 
heparinase I (HepI), which cleaves HS at the level of O-sulfated rather than non-sulfated or N-92 
sulfated disaccharides (Hovingh and Linker, 1970), resulted in a similar decrease of the Nogo-93 
A-20 inhibition but required higher enzyme concentrations (Figure S1A). 94 
If endogenous HS promotes the Nogo-A-20 inhibitory effects by directly binding to Nogo-95 
A, excess soluble HS in the culture medium may act as competitive inhibitor and neutralize 96 
Nogo-A-mediated cell spreading inhibition. Indeed, acute application of exogenous HS 97 
significantly increased cell spreading on a Nogo-A-20 substrate when compared to control 98 
treatment (Figure 1A,C). Similar effects were also observed when HS was added onto Nogo-99 
A-20-coated plates and washed prior to the plating of the cells, suggesting that Nogo-A-100 
20-bound HS neutralizes cell spreading inhibition (Figure S1B). 101 
To confirm the involvement of HS in Nogo-A-20 signaling, a HS-deficient mutant CHO cell 102 
line, pgsD-677 (Lidholt et al., 1992), was examined. Due to a mutation in the Ext1 gene 103 
encoding for a glycosyltransferase responsible for HS polymerization, pgsD-677 cells do not 104 
produce HS (Lidholt et al., 1992). Whereas wild type CHO cells were strongly inhibited in 105 
spreading by Nogo-A-20, spreading inhibition was almost fully abolished in the HSPG-106 
deficient pgsD-677 cells (Figure 1D,E). To confirm that these results are effectively due to the 107 
!!
lack of HS, we analysed cell spreading upon re-expression of Ext1 in pgsD-677 cells. Indeed, 108 
Ext1 re-expression fully restored Nogo-A-20-mediated cell spreading inhibition (Figure 109 
1D,F). The flow cytometry analysis of cell surface HSPGs expression confirmed their absence 110 
in pgsD-677 cells, as well as their partial reduction after HepIII treatment and their restoration 111 
after Ext1 re-expression (Figure 1G). 112 
Cell surface heparan sulfate is required for Nogo-A-20-induced inhibition of neurite 113 
outgrowth 114 
We examined the functional role of HS in Nogo-A-20-mediated inhibition of neurite 115 
outgrowth using postnatal day (P) 5-8 mouse cerebellar granule neurons (CGNs) as a model 116 
system. Notably, CGNs would not adhere if HepIII was applied acutely. Instead, HepIII was 117 
applied 12 h after plating for a total duration of 24 h. Delayed treatment of CGNs with HepIII 118 
fully abolished the growth-inhibitory effect of Nogo-A-20: neurite outgrowth was increased 119 
by ~92% when compared to the saline control (Figure 2A,B).  120 
To extend these findings to other neuronal populations, we analysed the effect of HepIII 121 
treatment in postnatal dorsal root ganglion (DRG) neurons and embryonic (E19) cortical 122 
neurons. Similar to CGNs, HepIII treatment fully abolished Nogo-A-20-induced inhibition 123 
of neurite outgrowth in DRG (Figure 2C,D) and cortical neurons (Figure 2E,F). Together, 124 
these results provide strong evidence for the requirement of HS chains on the surface of 125 
Nogo-A responsive cells to promote Nogo-A-20-mediated inhibition of neurite outgrowth. 126 
Nogo-A-20 binds heparan sulfate and brain-derived glycosaminoglycans 127 
To investigate a possible direct binding of Nogo-A-20 to HS, we used an ELISA assay. 128 
Biotinylated preparations of HS and heparin, a highly sulfated form of HS (Bernfield et al., 129 
1999), were immobilized and tested for T7-tagged Nogo-A-20 binding using two different 130 
antibodies: an anti-T7 tag and a Nogo-A-specific antibody targeting the 20 domain (11c7 131 
(Oertle et al., 2003)). To assess the binding specificity of Nogo-A-20 to HS, three different 132 
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variants of chondroitin sulfate (CS), another form of glycosaminoglycans (GAGs), were 133 
tested in parallel (CS-A, CS-C and CS-E). In addition, another inhibitory domain of Nogo-A, 134 
Nogo-66 (rat aa 1026-1091), which is known to interact with a different receptor complex 135 
(Kempf and Schwab, 2013), was tested. Importantly, Nogo-66 inhibits neurite outgrowth but 136 
not cell spreading (Kempf and Schwab, 2013). Recombinant Nogo-66-Fc was detected using 137 
an Fc-specific antibody. Nogo-A-20 but not Nogo-66 showed very strong binding to HS and 138 
to heparin and significantly less to CS-A, CS-C or CS-E (p < 0.001) (Figure 3A). These 139 
results were replicated using GAGs extracted from adult rat brains (total GAGs) treated with 140 
HepI/III or ChondroitinaseABC (ChABC) to obtain CS-containing GAGs (CS-GAGs) or HS-141 
containing GAGs (HS-GAGs), respectively. Consistent with the above results, Nogo-A-20 142 
bound total GAGs and HS-GAGs very strongly and showed significantly less binding to CS-143 
GAGs (p < 0.001) (Figure 3B). No binding of Nogo-66 to total GAGs, HS-GAGs or CS-144 
GAGs was observed (Figure 3B). In order to determine the specificity of the binding of Nogo-145 
A-20 to CS-GAGs, we tested the binding of the control protein Nogo-A-21 (rat aa 812-146 
918) (Oertle et al., 2003), which lacks inhibitory activity but is purified under identical 147 
conditions, to brain-derived GAGs. No difference in binding was observed between Nogo-A-148 
21, total GAGs, HS-GAGs or CS-GAGs (Figure S2). Moreover, the absorbance values lie in 149 
the same range than those of Nogo-A-20 binding to CS-GAGs, suggesting than the binding 150 
of Nogo-A-20 to CS-GAGs is likely to be unspecific. Given the fact that the results in 151 
Figure 3B, 3D and S2A are standardised against the total GAGs and that the HS:CS ratio in 152 
the brain is 1:10 (Deepa et al., 2006), Nogo-A-20 shows a strong binding preference to HS-153 
GAGs. Together, these results indicate that the key and main binding partner of Nogo-A-20 154 
is HS. 155 
Finally, to determine the binding affinity of Nogo-A-20 to heparin or HS-GAGs, a dose-156 
response binding curve was measured (Figure 3C,D). Binding was saturable and non-linear 157 
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fitting revealed that Nogo-A-20 binds to heparin and HS-GAGs with a dissociation constant 158 
(Kd) of ~234 nM and ~562 nM, respectively (Figure 3C, D). 159 
To assess the ability of Nogo-A-20 to bind HS under physiological conditions, cell surface 160 
binding assays were performed in CHO WT and pgsD-677 cells. Cells were incubated with 161 
HA-tagged Nogo-A-20 for 1 h at 4¡C, washed and immunostained for the HA tag (Figure 162 
3E). Nogo-A-20 binding was assessed by measuring the number of Nogo-A-20 puncta per 163 
cell surface area calculated upon 3D reconstruction of the cells. High numbers of Nogo-A-164 
20 puncta per WT CHO cell were found, whereas no binding of Nogo-A-20 was detected 165 
in CHO pgs-D677 cells (Figure 3F). Similar results were also obtained in 3T3 cells after 166 
HepIII treatment (Figure 3G) showing that Nogo-A-20 binds HSPGs.  167 
Nogo-A-20 acts via HSPGs independently of S1PR2 168 
Cell surface HSPGs can act as co-receptors by promoting the binding of a ligand to its 169 
obligate receptor and thereby altering its activation (Bernfield et al., 1999; Sarrazin et al., 170 
2011). Given the prior identification of the G-protein-coupled receptor (GPCR) Sphingosine-171 
1-Phosphate receptor 2 (S1PR2) as a functional receptor for Nogo-A-20 (Kempf et al., 172 
2014), HSPGs may enhance or allow the formation of a Nogo-A-20/S1PR2 complex. 173 
Alternatively, HSPGs may transduce Nogo-A-20 signals independently of S1PR2. In the 174 
latter case, we reasoned that HepIII treatment of S1PR2-deficient cells should show a 175 
disinhibition effect; in the former case, no effect of HepIII should be observed given the 176 
requirement of S1PR2 as obligate receptor. To test this, S1PR2
-/-
 mouse embryonic fibroblasts 177 
(MEFs) (Kempf et al., 2014) were treated with HepIII or saline and plated on Nogo-A-20 178 
(Figure 4A, S3A). Strikingly, treatment of S1PR2
-/-
 MEFs with HepIII significantly further 179 
increased cell spreading on Nogo-A-20 when compared to HepIII-treated WT MEFs or 180 
S1PR2
-/-
 MEFs alone (Figure 4A, S3A). This suggests that Nogo-A-20 can act via HSPGs 181 
independently of S1PR2. 182 
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In CHO-K1 WT cells, the levels of endogenous S1PRs mRNAs were shown to be below 183 
detection limit, and these cells were unresponsive to the S1PR family ligand S1P in a variety 184 
of in vitro assays (e.g., (Gonda et al., 1999; Okamoto et al., 1998)). Based on these 185 
observations, CHO-K1 WT cells are considered as devoid of S1PR expression. To validate 186 
this under our experimental conditions, CHO WT cells were treated with the pharmacological 187 
S1PR2 antagonist JTE-013 and plated onto Nogo-A-20 and control substrates (Figure 4B, 188 
S3B). As expected, JTE-013 did not antagonize Nogo-A-20-dependent inhibition of cell 189 
spreading (Figure 4B, S3B). The same observation was made in mutant pgsD-677 cells 190 
(Figure 4B, S3B). Together, these results suggest that Nogo-A-20 can exert inhibitory 191 
effects via HSPGs in S1PR2-deficient cellular systems.  192 
Nogo-A-20 has been repeatedly shown to activate the RhoA/ROCK pathway and thereby to 193 
inhibit cell spreading and neurite outgrowth (Kempf et al., 2014; Niederost et al., 2002). To 194 
test whether HSPGs can also mediate Nogo-A-20-induced downstream signaling, RhoA 195 
activation was measured in CHO WT and pgsD-677 cells. In CHO WT cells, a ~250% 196 
increase in RhoA activation was observed 20 min after application of Nogo-A-20, whereas 197 
no change was observed in pgsD-677 cells (Figure 4C,D). The inactive Nogo-A fragment 198 
Nogo-A-21 was used as control protein. Further, no change in RhoA activation was 199 
observed in the presence of JTE-013 (Figure S4A) suggesting the presence of an S1PR2-200 
independent, HSPG-dependent Nogo-A-20 signal transduction pathway. 201 
To determine whether Nogo-A-20 inhibition in CHO WT cells could be overcome by 202 
blocking RhoA or the downstream Rho-associated kinase (ROCK), CHO WT cell were 203 
treated with the RhoA inhibitor C3 transferase or with the ROCK inhibitor Y-27632 and 204 
plated onto Nogo-A-20 (Figure 4E,F). In line with the RhoA activation results, blockade of 205 
RhoA or ROCK showed a full rescue of Nogo-A-20 inhibition (Figure 4E,F). 206 
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Finally, in order to determine the effect of simultaneous blockade of HSPGs and S1PR2 in 207 
cells co-expressing HSPGs and S1PR2, 3T3 cells were treated with HepIII and/or JTE-013 208 
and assessed in a cell spreading assay. Strikingly, blockade of HSPGs and S1PR2 showed an 209 
additive effect in reducing Nogo-A-20 induced inhibition of cell spreading (Figure S3C,D). 210 
Hence, in cells co-expressing both receptors, Nogo-A-20 can exert inhibitory effects via 211 
both S1PR2 as well as HSPGs. However, as shown by using S1PR2-deficient cells, HSPGs 212 
are themselves sufficient to mediate Nogo-A-20 inhibition and RhoA activation. 213 
Syndecans mediate Nogo-A-20 inhibition of cell spreading and neurite outgrowth 214 
Membrane-bound cell surface HSPGs consist of two main families: syndecans and glypicans 215 
(Bernfield et al., 1999). As opposed to syndecans, glypicans are attached by a 216 
glycosylphosphatidylinositol anchor to the membrane and do not exert cytoplasmic signaling 217 
roles (Bernfield et al., 1999). The syndecan family consists of four members: syndecan-1 to 218 
syndecan-4 (Sdc1-Sdc4) (Bernfield et al., 1999), of which syndecan-4 is the most highly 219 
expressed in 3T3 cells (Figure 5A). Interestingly, syndecan-4 has been shown to activate 220 
RhoA to promote focal adhesion maturation and stress fibre assembly following engagement 221 
with fibronectin (Brooks 2012, Dovas 2006). 222 
To test the contribution of syndecan-4 to Nogo-A-20-induced inhibition of cell spreading 223 
and RhoA activation, syndecan-4 was knocked down using lentivirus-delivered ctrl and 224 
syndecan-4 shRNA (Figure S5A). Strikingly, knockdown of syndecan-4 fully prevented 225 
Nogo-A-20 inhibition of cell spreading (Figure 5B,C). To test whether Nogo-A-20 226 
activates RhoA via syndecan-4, RhoA activation assays were performed in ctrl vs syndecan-4 227 
shRNA cells. The inactive Nogo-A fragment Nogo-A-21 was used as control protein. No 228 
RhoA activation was observed upon syndecan-4 knockdown (Figure 5G). Together, these 229 
results suggest that Nogo-A-20 inhibits cell spreading by activating RhoA via syndecan-4 in 230 
fibroblasts. 231 
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To investigate whether syndecans are also important in Nogo-A-20-induced inhibition of 232 
neurite outgrowth, we first assessed their expression in DIV4 E19 rat cortical neurons and 233 
found syndecan-3 to be the most highly expressed (Figure 5D). Remarkably, siRNA-mediated 234 
knockdown of syndecan-3 fully prevented outgrowth inhibition on the Nogo-A-20 substrate 235 
(Figure 5E,F; S5B). 236 
Further, to test whether syndecan-3 and syndecan-4 directly interact with Nogo-A-20, 237 
microscale thermophoresis binding experiments were performed using recombinant syndecan-238 
3 and syndecan-4 ectodomains. We found that Nogo-A-20 binds to syndecan-4 and 239 
syndecan-3 in a similar affinity range than to brain-derived HS-GAGs with a Kd of ~522.1 nM 240 
and ~865.7 nM, respectively (Figure 5H). Taken together, these data show that Nogo-A-20 241 
binds to and exerts inhibitory effects via syndecan-3 or -4 in a cell type-specific manner. 242 
Nogo-A-20 promotes neuroblast migration via HSPGs 243 
Nogo-A-20 was shown to promote the tangential migration of neuroblasts from the 244 
subventricular zone (SVZ) to the olfactory bulb along the rostral migratory stream (RMS) 245 
through activation of the Rho/ROCK pathway (Rolando et al., 2012). Yet, no molecular basis 246 
for this observation was found and we sought to determine the physiological relevance of the 247 
Nogo-A-20/HSPG interaction in this process. 248 
To investigate the contribution of HSPGs to SVZ-derived neuroblast migration, postnatal 249 
explants of the SVZ and RMS were used as an ex vivo model (Wichterle et al., 1997) and 250 
treated with HepIII and/or the Nogo-A-20 function-blocking antibody 11c7. In this assay, 251 
neuroblasts move out of the explant core by chain migration (i.e. associated with each other) 252 
as occurs in the RMS in vivo (Wichterle et al., 1997). As previously shown, Nogo-A 253 
neutralization by 11c7 induced a significant reduction of the migration area (Figure 6A,B). 254 
HepIII treatment induced a similar reduction of the migration (Figure 6A,B). To examine 255 
whether HSPGs and Nogo-A-20 operate through the same pathway, we co-administered 256 
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HepIII and 11c7. Co-application of HepIII and 11c7 led to a reduction in migration area 257 
similar to that obtained upon treatment of HepIII or 11c7 alone (Figure 6A,B) suggesting that 258 
Nogo-A-20 operates through HSPGs in this system. 259 
Previous data suggested that Nogo-A sustains neuroblast migration by providing anti-260 
adhesive signals (Rolando et al., 2012). To investigate whether HSPGs participate in Nogo-A-261 
20-mediated repulsive effects, we asked whether HepIII treatment affected neuroblast 262 
adhesion on control vs. Nogo-A-20-coated substrates in the presence or absence of 11c7. 263 
HepIII treatment significantly increased cell adhesion on Nogo-A-20 to a similar extent than 264 
11c7 (Figure 6C). No additive or synergistic effects were observed (Figure 6C), suggesting 265 
that Nogo-A-20 and HSPGs share a common pathway in ex vivo cultures.  266 
Finally, to test the role of the previously identified Nogo-A-20 receptor S1PR2 in neuroblast 267 
migration, explants were treated with the S1PR2 blocker JTE-013 or DMSO (vehicle control). 268 
No significant effect on the migration area was observed using different concentrations of 269 
JTE-013 (Figure 6D,E). Similarly, JTE-013 treatment had no effect on neuroblast adhesion 270 
(Figure 6F). Taken together, these data show that Nogo-A-20 inhibits adhesion and 271 
increases migration by providing anti-adhesive signals through HSPGs but not S1PR2. 272 
  273 
!!
Discussion 274 
Cell-to-cell signaling by ligand receptor interactions as well as interactions with ECM 275 
constituents play key roles during developmental processes such as neuronal migration and 276 
axon growth. In this study, we identify a novel biochemical interaction between the 277 
membrane protein Nogo-A and HSPGs and demonstrate its functional significance in cell 278 
spreading, neurite outgrowth, adhesion and neuroblast chain migration.  279 
 280 
Cell surface HSPGs are traditionally viewed as co-receptors that promote the binding of a 281 
ligand to its obligate receptor through their large glycosaminoglycan chains (Bernfield et al., 282 
1999; Sarrazin et al., 2011) but do not act as signal-transducing receptors themselves. In the 283 
case of FGF and many other morphogens, HS is essential for the ligand/receptor complex to 284 
form and to alter its activation (Sarrazin et al., 2011). Surprisingly, our data suggest that this 285 
is not the case for Nogo-A-20 and its S1PR2 receptor (Kempf et al., 2014): Nogo-A-20 can 286 
activate RhoA in S1PR-negative CHO cells and inhibits cell spreading in S1PR2
-/-
 MEFs. 287 
Hence, our results strongly suggest that Nogo-A-20 can signal through S1PR-independent 288 
mechanisms. However, when HSPGs and S1PR2 are co-expressed, both pathways can act in 289 
parallel, as shown for fibroblasts, or one pathway can gain control of the signaling output, as 290 
demonstrated for neuroblasts. Collectively, our experiments reveal that more than one 291 
receptor for the active Nogo-A-20 region exists and that Nogo-A-20-induced inhibitory 292 
effects are regulated in a cell type-specific manner. 293 
 294 
Based on our findings showing the involvement of syndecan-3 and syndecan-4, we may 295 
hypothesize that the cytoplasmic tail of syndecans is important for Nogo-A-20-induced 296 
signal transduction upon extracellular binding to the HS chains. A few studies have shown 297 
that transmembrane syndecans can act as signaling receptors through their cytoplasmic 298 
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domains. During cell migration, engagement of syndecan-4 by fibronectin was shown to 299 
result in the activation of protein kinase C  (PKC) upstream of RhoA activation (Bass et 300 
al., 2008; Bass et al., 2007; Brooks et al., 2012; Dovas et al., 2006). Even though it is unclear 301 
how syndecan-4 signals to RhoA via PKC,  PKC was shown to activate RhoA via 302 
phosphorylation of the Rho guanine exchange factor (RhoGEF) p115 in a different system 303 
(Peng et al 2011). It will be interesting to investigate whether Nogo-A-20 operates via 304 
similar mechanisms. In the case of syndecan-3, binding of the heparin-binding growth-305 
associated molecule HB-GAM was shown to result in phosphorylation of the Src kinases c-306 
Src and c-Fyn, and of cortactin, which promotes polymerization and rearrangement of the 307 
actin cytoskeleton resulting in neurite outgrowth (Kinnunen et al., 1998). A similar 308 
mechanism was proposed for glial cell line-derived neurotrophic factor (GDNF) family 309 
ligands and syndecan-3 (Bespalov et al., 2011). However, no link between syndecan-3 and 310 
RhoA activation has been reported so far and future studies shall address this point. 311 
 312 
Syndecan-3 is the major HSPG found in neurons of the developing brain and shows abundant 313 
expression in major axonal tracts and migratory routes, e.g., in the RMS (Hienola et al., 2006; 314 
Nolo et al., 1995; Rauvala et al., 2000). In the adult brain, syndecan-3 is strongly expressed in 315 
the hippocampus, cerebellum and cortex and in several axonal tracts (Hsueh and Sheng, 316 
1999). Our results show that the anti-adhesive effect of Nogo-A-20 is accompanied by an 317 
HS-dependent increase in neuroblast chain migration. Notably, syndecan-3
-/-
 mice phenocopy 318 
the defects in radial and tangential neuronal migration observed in Nogo-A
-/-
 mice (Hienola et 319 
al., 2006; Mathis et al., 2010; Mingorance-Le Meur et al., 2007; Rolando et al., 2012). 320 
Syndecan-3
-/-
 mice also display a synaptic plasticity phenotype similar to that observed in 321 
Nogo-A
-/-
 mice: increased CA1 long-term potentiation (LTP) while baseline transmission and 322 
short-term plasticity are not affected (Kaksonen et al., 2002). Given the recent implication of 323 
!!
HSPGs in synapse formation and plasticity (Allen et al., 2012; de Wit et al., 2013; Siddiqui et 324 
al., 2013), it will be interesting to determine whether Nogo-A also mediates its effects on 325 
synapse formation and plasticity via HSPGs (Mironova and Giger, 2013). Overall, the 326 
localization of syndecan proteins and their physiological impact in the developing and adult 327 
brain are consistent with a functional interaction between Nogo-A and HSPGs in vivo. 328 
 329 
In conclusion, our study shows that Nogo-A-20 can regulate adhesion, cell spreading, 330 
outgrowth and migration of various cell lines, neurons and neuroblasts via a newly identified 331 
interaction with transmembrane HSPGs. 332 
  333 
!!
Experimental procedures 334 
Plasmids, recombinant fusion proteins, reagents, antibodies and brain-derived 335 
glycosaminoglycans (GAGs) 336 
A complete description is provided in the Supplemental Experimental Procedures. 337 
Tissue preparation and cell culture 338 
A complete description is provided in the Supplemental Experimental Procedures. 339 
Immunocytochemistry, flow cytometry and RhoA activation assays 340 
Immunocytochemistry, cell surface binding assays, flow cytometry and RhoA 341 
pulldown/ELISA experiments were essentially performed as previously described (Kempf et 342 
al., 2014). A complete description is provided in the Supplemental Experimental Procedures. 343 
In vitro bioassays 344 
3T3 fibroblast spreading assays and neurite outgrowth assays were performed as described 345 
previously (Kempf et al., 2014; Oertle et al., 2003). For HepI and HepIII (Sigma) treatment, 346 
cells were incubated with 2.5-10 U/ml HepI or HepIII 3 h prior plating and during the 347 
spreading assay. For function-blocking experiments, cells were incubated with 1 µM JTE-348 
013, 5 µM Y-27632 or 100 µg/ml C3 30 min prior plating and during the spreading assay. 349 
The corresponding solvents were used as controls. For expression of EXT1 in pgsD-677 cells, 350 
pgsD-677 cells were transfected with Ext1 cDNA using Lipofectamine 2000 (Invitrogen) 351 
according to the manufacturerÕs instructions. For siRNA experiments, 3T3 cells or E19 rat 352 
cortical neurons were transfected with ON-TARGETplus SMARTpool siRNAs using 353 
DharmaFECT3 (Dharmacon) according to the manufacturerÕs instructions. For shRNA 354 
experiments, stable 3T3 shRNA cell lines were made using lentiviruses carrying Mission 355 
shRNA pLKO lentiviral plasmids (Sigma) containing shRNA against Sdc4 or ctrl shRNA. A 356 
complete description is provided in the Supplemental Experimental Procedures. 357 
ELISA 358 
!!
The ELISA was performed according to method described in (Purushothaman et al., 2007) 359 
with modifications detailed in Supplemental Experimental Procedures.  360 
Explant assay 361 
P5 explants were prepared from C57/BL6 pups according to (Wichterle et al., 1997) with 362 
modifications detailed in Supplemental Experimental Procedures.  363 
Statistical analysis 364 
Statistical analyses were conducted using the statistical software GraphPad Prism 5 or 6 365 
(GraphPad Software Inc.). *p < 0.05 was considered statistically significant. Calculations 366 
were corrected for multiple comparisons as specified.  367 
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Figure legends 490 
 491 
Figure 1. Cell surface HSPGs mediate Nogo-A-20 inhibition of cell spreading. A. 492 
Representative pictures of 3T3 fibroblasts treated with 2.5 U/ml HepIII, 0.1 mg/ml HS or 493 
vehicle (saline) and plated on control (ctrl) or Nogo-A-20 substrate. Cells were stained with 494 
Phalloidin-Alexa488. B,C. Cell spreading quantification of A. HepIII (B) or HS (C) treatment 495 
partially reversed Nogo-A-20-mediated cell spreading inhibition. D. Representative pictures 496 
of CHO WT, CHO pgsD-677 or CHO pgsD-677 expressing Ext1 cDNA and plated on a 497 
control or Nogo-A-20 substrate. E,F. Cell spreading quantification of D. E. The rounding 498 
response to Nogo-A-20 is highly impaired in CHO pgsD-677 mutants. F. Expression of 499 
EXT1 in CHO pgsD-677 cells fully restored Nogo-A-20 inhibition. G. Flow cytometry 500 
detection of cell surface HSPGs in 3T3 cells (upper panel) or CHO WT and pgsD-677 cells 501 
(lower panel) using the 10E4 antibody. HepIII treatment of 3T3 cells reduces HSPG levels. 502 
EXT1 expression restores HSPG levels in CHO pgsD-677 cells. WT designates CHO cells. 503 
Filled grey curves indicate unstained controls. The fluorescence intensity is displayed on the 504 
X-axis (256 bins) and the normalized number of cells per each bin on the Y-axis. Data shown 505 
are means ± SEM (n = 8-12 coverslips). B,C,E,F: One-way ANOVA with TuckeyÕs post hoc 506 
test; (*** p < 0.001). Scale bars: 45 µm. See also Figure S1. 507 
Figure 2. Cell surface HSPGs mediate Nogo-A-20 inhibition of neurite outgrowth. A. 508 
Representative pictures of mouse P7 cerebellar granule neurons (CGNs) treated with 509 
500 mU/ml HepIII or vehicle (saline) and plated on a control (ctrl) or Nogo-A-20 substrate. 510 
Neurons were stained with III-Tubulin. B. Total neurite length per cell quantification of A. 511 
HepIII treatment fully reversed Nogo-A-20-mediated inhibition of neurite outgrowth. C. 512 
Representative pictures of mouse P7 dorsal root ganglia (DRG) neurons treated with 1 U/ml 513 
HepIII or vehicle (saline) and plated on a control or Nogo-A-20 substrate. Neurons were 514 
!!
stained with III-Tubulin. D. Total neurite length per cell quantification of C. E. 515 
Representative pictures of DIV5 rat E19 cortical neurons treated with 1 U/ml HepIII or 516 
vehicle (saline) at DIV4 and replated on a control (ctrl) or Nogo-A-20 substrate for 24h. 517 
Neurons were stained with Map1b. F. Total neurite length per cell quantification of E. DIV, 518 
days in vitro. Data shown are means ± SEM (n = 3-9 coverslips). B,D,F: One-way ANOVA 519 
with TuckeyÕs post hoc test; (* p < 0.05, *** p < 0.001; ns: not significant). Scale bars: 520 
45 µm. 521 
Figure 3. Nogo-A-20 but not Nogo-66 binds Heparin and HS. A-D. Biotinylated heparin, 522 
HS, CS or brain-derived GAGs were coated onto streptavidin-coated wells and analysed for 523 
Nogo-A-20 or Nogo-66 binding by an ELISA-type assay. Average values for the BSA 524 
negative control were subtracted from the respective readings. Nogo-A-20-T7 binding was 525 
detected using an anti-T7 or anti-Nogo-A (11c7) antibody and Nogo-66-Fc binding using an 526 
anti-Fc antibody. A. Binding analysis of Nogo-A-20 and Nogo-66 to Heparin, HS, CS-A, 527 
CS-C or CS-E. B. Binding analysis of Nogo-A-20 and Nogo-66 to brain-derived GAGs 528 
treated with heparinase (CS-GAGs) or chondroitinase ABC (HS-GAGs). Total GAGs refer to 529 
the untreated GAG fraction. C. Saturation curve of Nogo-A-20 to heparin (Kd ~ 234nM) and 530 
brain-derived HS-GAGs (Kd ~ 562nM). Detection was performed using the anti-T7 antibody. 531 
D. Scatchard plot of C. E. Representative images of cell surface binding of Nogo-A-20 to 532 
CHO WT and HSPG-deficient CHO pgsD-677 cells. Cells were incubated with 1 µM HA-533 
tagged Nogo-A-20 for 30 min on ice and stained using the anti-HA antibody. F,G. 534 
Quantification of cell surface binding by assessing the number of bound HA-tagged Nogo-A-535 
20 spots in CHO WT and pgsD-677 cells (F) or in HepIII vs. saline-treated 3T3 cells (G). 536 
Average values for the control were subtracted from the respective measurements. Data 537 
shown are means ± SEM (A-D: n = 3 experiments; F: n = 10 cells; G: n = 30-34 cells). A,B: 538 
One-way ANOVA with TuckeyÕs post hoc test; F,G: Mann Whitney test (*** p < 0.001).  539 
!!
Figure 4. HSPGs mediate Nogo-A-20 signaling independently of S1PR2. A. Cell 540 
spreading quantification of CHO WT and CHO pgsD-677 cells treated with 1 µM JTE-013 or 541 
vehicle (DMSO) and plated on a control (ctrl) or Nogo-A-20 substrate. Representative 542 
pictures are shown in Figure S3A. B. Cell spreading quantification of WT and S1PR2
-/-
 MEFs 543 
treated with 2.5 U/ml HepIII or vehicle (saline) and plated on a control (ctrl) or Nogo-A-20 544 
substrate. Representative pictures are shown in Figure S3B. C. RhoA activation was assessed 545 
in CHO WT and pgsD-677 cells 20 min post-incubation with 1 µM Nogo-A-20 by western 546 
blotting. D. Quantification of RhoA-GTP/Total RhoA levels shown in C. Nogo-A-20 does 547 
not activate RhoA in pgsD-677 cells. E. Representative pictures of CHO WT cells treated 548 
with the RhoA inhibitor C3 transferase (0.1 mg/ml), the ROCK blocker Y-27632 (5 µM) or 549 
vehicle (saline). F. Cell spreading quantification of E. Data shown are means ± SEM (B,F: 550 
n = 6-16 coverslips; D: n = 3 experiments. B,D,F: One-way ANOVA with TuckeyÕs post hoc 551 
test (** p < 0.01; *** p < 0.001). Scale bars: 45 µm. See also Figure S3 and S4. 552 
Figure 5. Syndecans mediate Nogo-A-20 of cell spreading and neurite outgrowth. A. 553 
qRT-PCR expression analysis of syndecans (Sdc) in 3T3 cells. mRNA fold changes are 554 
normalized to Sdc1 (100%). B. Representative pictures of 3T3 cells treated with a lentivirus 555 
expressing Sdc4 or ctrl shRNA for 96 h and replated on a ctrl or Nogo-A-20 substrate for 556 
1 h. Cells were stained with Phalloidin-Alexa488. C. Cell spreading quantification of B. D. 557 
qRT-PCR expression analysis of SdcÕs in DIV4 rat E19 cortical neurons. mRNA fold changes 558 
are normalized to Sdc1 (100%). E. Representative pictures of DIV8 rat cortical neurons 559 
treated at DIV4 with ctrl or Sdc3 siRNA for 72 h and replated on a ctrl or Nogo-A-20 560 
substrate for 24 h. Cells were stained with MAP1b. F. Neurite length quantification of E. G.  561 
RhoA activation was assessed in 3T3 cells expressing Sdc4 or ctrl shRNA 20 min post-562 
incubation with 1 µM Nogo-A-20 using a commercially available ELISA kit. Quantification 563 
of RhoA-GTP/Total RhoA levels is shown. H. Microscale binding analysis of Nogo-A-20 to 564 
!!
recombinant mouse Sdc4 (Kd ~ 522.1nM) or Sdc3 (Kd ~ 865.7nM). Single dots indicate 565 
biological replicates in A and D. Data shown are means ± SEM (A,D: n = 3 experiments; G: 566 
n = 6 experiments; C,F: n = 8-16 coverslips). C,F,G: One-way ANOVA with TuckeyÕs post 567 
hoc test (* p < 0.05, *** p < 0.001; ns: not significant). Scale bars: 45 µm. See also Figure S5. 568 
Figure 6. Nogo-A-20 regulates neuroblast adhesion and migration via HSPGs. A. 569 
Representative pictures of neuroblast explants (SVZ+RMS) showing the decrease in 570 
migration area of HepIII (500 mU/ml), 11c7 (1 µg/µl) and HepIII+11c7-treated explants vs. 571 
controls. B. Quantification of the migration area. Controls are set to 100% for each 572 
experiment. C. Adhesion of SVZ-dissociated neuroblasts on a Nogo-A-20 substrate after 573 
treatment with 11c7 and/or HepIII. No synergistic activity is detected by co-treatment of 574 
neuroblasts with 11c7 and HepIII in B and C. D. Representative pictures of neuroblast 575 
explants (SVZ+RMS) treated with different concentrations of JTE-013 or vehicle (DMSO). 576 
E. Quantification of the migration in the presence of JTE-013 vs. DMSO. Controls are set to 577 
100% for each experiment. F. Adhesion of SVZ-dissociated neuroblasts on a Nogo-A-20 578 
substrate after treatment with JTE-013 or DMSO. No significant effect is observed upon 579 
treatment with JTE-013 in E and F. Data shown are means ± SEM (B: n = 4-5 experiments; 580 
C: n = 3 coverslips; E: n = 4-5 experiments, F: n = 5 coverslips). B,C,E,F: One-way ANOVA 581 
with BonferroniÕs post hoc test (* p < 0.05, ** p < 0.01, *** p < 0.001). Scale bars: A: 582 
100 µm. 583 
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Figure S1. Related to Figure 1. Effect of HepI treatment and pre-incubation of HS and Nogo-A-'20 on Nogo-A-
'20-induced inhibition of cell spreading. A. Cell spreading quantification of 3T3 fibroblasts treated with 2.5 U/ml 
HepI, 10 U/ml HepI or vehicle (saline) and plated on control (ctrl) and Nogo-A-'20 substrates. B. Cell spreading 
quantification of 3T3 fibroblasts plated on a substrate consisting of Nogo-A-'20 pre-incubated with HS (0.1 
mg/ml). Data shown are means ± SEM (A,B: n = 3-6 coverslips). A,B: One-way ANOVA with Tuckey’s post hoc 
test (* p < 0.05, ** p < 0.01).
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Figure S2. Related to Figure 3. Binding of Nogo-A-'21 to brain-derived GAGs. A. Biotinylated brain-derived 
GAGs treated with heparinase (CS-GAGs) or chondroitinase ABC (HS-GAGs) or untreated (total GAGs) were 
coated onto streptavidin-coated wells and analysed for Nogo-A-'21 binding by an ELISA-type assay. Average 
values for the BSA negative control were substracted from the respective readings. Nogo-A-'21-T7 binding was 
detected using an anti-T7 antibody. Data shown are means ± SEM (A,B: n = 3 experiments). A: One-way ANOVA 
with Tuckey’s post hoc test (ns: not significant).
Figure S3. Related to Figure 4. Effects of S1PR2 blockade/knockout and HepIII treatment. A. Representative 
pictures of WT and S1PR2-/- MEFs treated with 2.5 U/ml HepIII or vehicle (saline) and plated on control (ctrl) 
and Nogo-A-'20 substrates. B. Representative pictures of CHO WT and CHO pgsD-677 cells treated with 1 PM 
JTE-013 or vehicle (DMSO) and plated on control (ctrl) and Nogo-A-'20 substrates. Quantification of A and B 
is shown in Figure 4A and 4B. C. Representative pictures of 3T3 cells treated with 2.5 U/ml HepIII or vehicle 
(saline) and plated on a control (ctrl) or Nogo-A-'20 substrate in the presence of 1 PM JTE-013 or vehicle 
(DMSO). D. Co-treatment with HepIII and JTE-013 led to an additive effect on Nogo-A-'20 inhibition rescue in 
3T3 cells. Data shown are means ± SEM (B,D: n = 5-9 coverslips). B,D: One-way ANOVA with Tuckey’s post 
hoc test (** p < 0.01; *** p < 0.001; ns: not significant). Scale bars: 45 Pm.
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Figure S4. Related to Figure 4. JTE-013 treatment does not affect RhoA activation in S1PR2-negative CHO cells. 
A. RhoA activation was assessed in CHO WT cells 20 min post-incubation with 1 PM Nogo-A-'20 using an 
ELISA kit. Data shown are means ± SEM (n = 3 experiments). Mann Whitney test (ns: not significant).
Figure S4
A
0
100
200
300
400
DMSO
JTE-013
Ctrl '20 
R
ho
A
-G
TP
 
/
To
ta
l R
ho
A 
(%
)
ns
Figure S5
0.0
0.5
1.0
ctrl siRNA
Sdc3 siRNA
Sd
c3
 m
RN
A
fo
ld
 c
ha
ng
e 
( )
B
0.0
0.5
1.0
ctrl shRNA
Sdc4 shRNA
Sd
c4
 m
RN
A
fo
ld
 c
ha
ng
e 
( )
A
Figure S5. Related to Figure 5. Knockdown efficiency of syndecan shRNA and siRNA constructs. A. Quantita-
tive RT-PCR analysis of 3T3 cells expressing lentivirally delivered syndecan-4 (Sdc4) shRNA for 96 h. Scrambled 
shRNA (ctrl) was used as control and set to 1. Relative quantification of expression levels: Sdc4 (0.460 ± 0.186). 
B. Quantitative RT-PCR analysis of E19 cortical neurons treated at DIV4 with syndecan-3 (Sdc3) or scrambled 
(ctrl) siRNA for 72 h. Scrambled siRNA was set to 1. Relative quantification of expression levels: Sdc3 (0.673 ± 
0.099). Data shown are means ± SEM (A,B: n = 3-4 experiments).
 Supplemental Figure Legends 1 
 2 
Figure S1. Related to Figure 1. Effect of HepI treatment and pre-incubation of HS and Nogo-A-20 on 3 
Nogo-A-20-induced inhibition of cell spreading. A. Cell spreading quantification of 3T3 fibroblasts treated 4 
with 2.5 U/ml HepI, 10 U/ml HepI or vehicle (saline) and plated on control (ctrl) and Nogo-A- 20 substrates. B. 5 
Cell spreading quantification of 3T3 fibroblasts plated on a substrate consisting of Nogo-A- 20 pre-incubated 6 
with HS (0.1 mg/ml). Data shown are means ± SEM (A,B: n = 3-6 coverslips). A,B: One-way ANOVA with 7 
TuckeyÕs post hoc test (* p < 0.05, ** p < 0.01). 8 
 9 
Figure S2. Related to Figure 3. Binding of Nogo-A-21 to brain-derived GAGs. A. Biotinylated brain-derived 10 
GAGs treated with heparinase (CS-GAGs) or chondroitinase (HS-GAGs) or untreated (total GAGs) were coated 11 
onto streptavidin-coated wells and analysed for Nogo-A-21 binding by an ELISA-type assay. Average values 12 
for the BSA negative control were substracted from the respective readings. Nogo-A-21-T7 binding was detected 13 
using an anti-T7 antibody. Data shown are means ± SEM (A,B: n = 3 experiments). A: One-way ANOVA with 14 
TuckeyÕs post hoc test (ns: not significant). 15 
 16 
Figure S3. Related to Figure 4. Effects of S1PR2 blockade/knockout and HepIII treatment. A. 17 
Representative pictures of WT and S1PR2
-/-
 MEFs treated with 2.5 U/ml HepIII or vehicle (saline) and plated on 18 
control (ctrl) and Nogo-A-20 substrates. B. HepIII treatment of S1PR2
-/-
 MEFs led to an additive effect on Nogo-19 
A-20 inhibition rescue as opposed to S1PR2 knockout or HepIII treatment alone. C. Representative pictures of 20 
3T3 cells treated with 2.5 U/ml HepIII or vehicle (saline) and plated on a control (ctrl) or Nogo-A-20 substrate 21 
in the presence of 1 µM JTE-013 or vehicle (DMSO). D. Co-treatment with HepIII and JTE-013 led to an additive 22 
effect on Nogo-A-20 inhibition rescue in 3T3 cells. Data shown are means ± SEM (B,D: n = 5-9 coverslips). 23 
B,D: One-way ANOVA with TuckeyÕs post hoc test (** p < 0.01; *** p < 0.001; ns: not significant). Scale bars: 24 
45 µm. 25 
 26 
Figure S4. Related to Figure 4. JTE-013 treatment does not affect RhoA activation in S1PR2-negative CHO 27 
cells. RhoA activation was assessed in CHO WT cells 20 min post-incubation with 1 µM Nogo-A-20 using an 28 
ELISA kit. Data shown are means ± SEM (n = 3 experiments). Mann Whitney test (ns: not significant). 29 
 30 
Figure S5. Related to Figure 5. Knockdown efficiency of syndecan shRNA and siRNA constructs. A. 31 
Quantitative RT-PCR analysis of 3T3 cells expressing lentivirally delivered syndecan-4 (Sdc4) shRNA for 96 h. 32 
Scrambled shRNA (ctrl) was used as control and set to 1. Relative quantification of expression levels: Sdc4 33 
(0.460 ± 0.186). B. Quantitative RT-PCR analysis of E19 cortical neurons treated at DIV4 with syndecan-3 (Sdc3) 34 
or scrambled (ctrl) siRNA for 72 h. Scrambled siRNA was set to 1. Relative quantification of expression levels: 35 
Sdc3 (0.673 ± 0.099). Data shown are means ± SEM (A,B: n = 3-4 experiments). 36 
 37 
  38 
 Supplemental Experimental Procedures 39 
 40 
Recombinant fusion proteins, reagents and antibodies 41 
Recombinant proteins Nogo-A-Δ20 (rat aa544-725) and Nogo-A-Δ21 (rat aa812-918) were purified as described 42 
previously (Oertle et al., 2003). Briefly, BL21/DE3 E. coli were transformed with the pET28 expression vector 43 
(Novagen) containing His-/T7-tagged Nogo-A-Δ20, His-/T7-tagged Nogo-A-Δ21 or His-/HA-tagged Nogo-A-44 
Δ20 and cultured at 37¡C to reach an OD of 0.6 AU. Protein expression was induced by addition of 1 M IPTG for 45 
2 h at 30¡C. Fusion proteins were purified using Co
2+
-Talon Metal Affinity Resin (Takara Bio Inc.).  46 
CS variants and HS were purchased from Seikagaku Corp (Japan) where CS-A is isolated from whale cartilage, 47 
CS-C is from shark cartilage, CS-E is from squid cartilage and HS is from bovine kidney. The biotinylated-heparin 48 
isolated from porcine intestine was purchased from Sigma. 49 
The following primary antibodies were used: mouse anti-βIII Tubulin (Promega G712A, clone 5G8; ICC: 1:1000), 50 
4Õ,6-diamidino-2-phenylindole (DAPI) (Invitrogen D1306; ICC: 1:1000), mouse anti-GAPDH (Abcam, ab8245; 51 
1:20,000), rat anti-HA tag (Roche 11867423001; ICC: 1:200), mouse anti-heparan sulfate (Seikagaku Corp 52 
370255-1, clone F58-10E4; FACS: 1฀µg/106 cells), mouse IgM isotype control (BD Pharmingen 557275, clone 53 
C48-6; FACS: 1฀µg/106 cells), goat anti-mouse IgG, Fc fragment specific (Jackson Immunoresearch 115-005-54 
071; ELISA: 1฀µg/ml), mouse anti-Map-1b (Santa Cruz sc-58784, clone AA6; ICC 1:2000), mouse anti-Nogo-55 
A (11c7, (Oertle et al., 2003), ELISA: 1฀µg/ml), Phalloidin-Alexa488 (Invitrogen A12379; ICC: 1:500), rabbit 56 
anti-RhoA (Cell Signaling 2117; WB: 1:1000), mouse anti-T7 tag (Novagen 69522-3; ELISA: 1฀µg/ml). 57 
The following secondary antibodies were used: goat anti-mouse IgG Alexa488-conjugated (Invitrogen A11029; 58 
ICC: 1:1000), rat anti-mouse IgM FITC-conjugated (BD Pharmingen 553437, clone II/41; FACS: 1:1000), HRP-59 
conjugated goat anti-rabbit IgG (Jackson Immunoresearch). 60 
 61 
Brain derived glycosaminoglycans (GAGs) 62 
Adult Sprague Dawley rats were sacrificed and decapitated. The brains were cut into smaller pieces before de-63 
lipidation with cold acetone. The tissues were then dried and homogenized in cold pronase buffer. The brain was 64 
then treated with pronase overnight and the proteins/peptides were removed by precipitation using trichloroacetic 65 
acid, followed by centrifugation. The residual trichloroacetic acid retained in the supernatant (which contains the 66 
GAGs) is removed with 5 diethyl ether washes. The GAGs were precipitated with sodium acetate and absolute 67 
ethanol overnight at 4¡C and recovered after centrifugation. The resulting pellet will be reconstituted in 500 µl of 68 
de-ionized water and stored at -20¡C. 69 
 70 
Tissue preparation and cell culture 71 
Total myelin protein extracts were prepared from the spinal cords of adult Wistar rats as described previously 72 
(Oertle et al., 2003). Swiss 3T3 (ATCC) cells and primary mouse embryonic fibroblasts (MEFs) were maintained 73 
in DulbeccoÕs modified eagle medium (DMEM) (Sigma, Invitrogen) containing 10% neonatal calf serum 74 
(Invitrogen). CHO K1 WT (ATCC) and CHO pgsD-677 cells (ATCC) were maintained in DMEM containing 75 
10% fetal bovine serum (FBS) (Invitrogen). Primary S1PR2
-/-
 MEFs were described previously (Kempf et al., 76 
2014).฀P5-8 mouse CGNs, P5-8 mouse DRG neurons and E19 rat cortical neurons were prepared as described 77 
previously (Kempf et al., 2014; Oertle et al., 2003). HEK293T (ATCC) cells were maintained in IscoveÕs modified 78 
DulbeccoÕs medium (IMDM) (Life Technologies) medium supplemented with 4 mM L-Glutamine (Sigma), 1% 79 
Penicillin/Streptomycin (Pen/Strep) (Life Technologies) and 10% FBS. Swiss 3T3 ctrl shRNA and Sdc4 shRNA 80 
cells were selected with 4µg/mL puromycin. All cell lines and primary cells were cultured at 37¡C and 5% CO2. 81 
 82 
Immunocytochemistry 83 
Cell lines and primary cells were fixed with 4% paraformaldehyde (PFA) for 15 min, washed and permeabilized 84 
with 0.1% Triton X-100. After blocking with 2% goat serum, cells were first incubated with the primary antibodies 85 
for 30 min at room temperature and detected using corresponding secondary antibodies in 2% goat serum.  86 
For cell surface immunocytochemical detection of Nogo-A-Δ20, cells were first incubated with 1 µM HA-tagged 87 
Nogo-A-Δ20 and subsequently with anti-HA antibodies for 1 h each on ice in serum-free medium containing 88 
0.02% sodium azide (Sigma). Cells were washed, fixed with 1% PFA and stained with secondary antibodies. 89 
Image stacks were acquired using a Leica SP5 confocal microscope equipped with a 63x oil immersion objective 90 
(NA 1.4). Stacks were reconstructed in 3D with Imaris (Bitplane) and the cell surface area was measured for each 91 
cell. Bound Nogo-A-Δ20 puncta were counted using the spot function of Imaris and the total number was 92 
normalized to the cell surface area for each cell. The average ratio obtained with secondary antibody only controls 93 
was baseline-subtracted from each cell.  94 
 95 
Flow cytometry 96 
 For FACS analysis, non-fixed cells were detached using 0.05% Trypsin/EDTA (Invitrogen), washed 1x in PBS, 97 
washed 2x in Tris-Buffer/1%BSA at 4¡C and stained with the indicated primary antibodies followed by 98 
fluorescently-conjugated secondary antibodies for 30 min each in Tris-Buffer/5%BSA on ice. Cells were 99 
immediately analyzed by FACS (BD Canto II). FACS staining was quantitated using the FlowJo (Tree Star Inc) 100 
software. The fluorescence intensity is displayed on the X-axis (divided into 256 bins). The % of Max on the Y-101 
axis stands for the number of cells in each bin on the X-axis (FlowJo uses an arbitrary number of 256 bins) divided 102 
by the number of cells in the bin that contains the largest number of cells.  103 
 104 
RhoA activation assays 105 
3T3 cells were serum-starved overnight and treated for 20 min with 1 µM Nogo-A-Δ20 or Nogo-A-Δ21 control 106 
protein. Pulldown of activated RhoA-GTP was subsequently performed using the RhoA Activation Assay 107 
Biochem Kit according to the manufacturer's instructions (Cytoskeleton, Inc.). Alternatively, RhoA activation 108 
was assessed using the total RhoA ELISA and RhoA G-LISA kit according to the manufacturer's instructions 109 
(Cytoskeleton, Inc.). Levels of activated RhoA were normalized to total RhoA levels for each biological replicate. 110 
 111 
In vitro bioassays 112 
3T3 fibroblast spreading assays and neurite outgrowth assays were performed as described previously (Kempf et 113 
al., 2014; Oertle et al., 2003). Briefly, 4-well plates (Greiner) were coated with 40-100 pmol/cm
2
 (0.4-1 µM) 114 
Nogo-A-Δ20 or Nogo-A-Δ21 (control protein) or 5 µg/cm
2 
myelin at 4¡C overnight. In outgrowth experiments, 115 
wells were precoated with 0.3 µg/ml Poly-L-Lysine (PLL; Sigma) for 1 h at 37¡C before the addition of the 116 
different substrates. Unbound material was removed by three washes with PBS. Cell lines were detached with 2% 117 
(w/v) EDTA in PBS and plated at 7000 cells per cm
2
 for 1 h at 37¡C and 5% CO2, fixed with 4% PFA and stained 118 
with Phalloidin-Alexa488. For HepI and HepIII (Sigma) treatment, cells were incubated with 2.5 U/ml HepIII or 119 
2.5-10 U/ml HepI 3 h prior plating and during the spreading assay. Higher concentrations of HepIII could not be 120 
used under our experimental conditions because of their effects on cell viability. For JTE-013 (Tocris), Y-27632 121 
(Sigma) and cell-permeable C3 transferase (CT04, Cytoskeleton), cells were incubated with 1 µM JTE-013, 5 µM 122 
Y-27632 or 100 µg/ml C3 30 min prior plating and during the spreading assay. The corresponding solvents or 123 
isotype antibodies were used as controls. For expression of EXT1 in pgsD-677 cells, pgsD-677 cells were 124 
transfected with Ext1 cDNA using Lipofectamine 2000 (Invitrogen) 48 h prior replating according to the 125 
manufacturerÕs instructions. The percentage of cells that remained round i.e. did not spread was quantified 126 
manually in four randomly chosen areas of the well/coverslip and averaged over those areas (n = 1 coverslip). 127 
Data were normalized to baseline and plotted as mean ± SEM from multiple biological replicates. 128 
CGNs were plated at 7.5x10
4
 cells per cm
2
, DRGs at 7.5x10
3
 cells per cm
2
 and cortical neurons at 5x10
4
 cells per 129 
cm
2
 onto the various substrates. Neurons were cultured for 24-48 h at 37¡C and 5% CO2, fixed with 4% PFA and 130 
stained with anti-βIII Tubulin (CGNs and DRGs) or Mab1b (cortical neurons). Treatment of CGNs with 131 
500 mU/ml HepIII and DRGs with 1 U/ml HepIII started 12 h post-plating until fixation. Cortical neurons were 132 
treated at DIV4 with 1 U/ml HepIII for 3 h and replated for 24 h in the presence of HepIII. The corresponding 133 
solvents were used as control. Neurons were imaged with an Axioskop 2 microscope (Zeiss) equipped with a 134 
Plan-NEOFLUAR 10X/NA 0.3 objective in a semi-automated way. Mean total neurite length per cell was 135 
quantified using the MetaMorph software (Molecular Devices) in four randomly chosen areas of the 136 
well/coverslip and averaged over those areas (n = 1 coverslip). Data were normalized to baseline and plotted as 137 
mean ± SEM from multiple biological replicates. 138 
 139 
siRNA/shRNA 140 
E19 rat cortical neurons were plated at 0.6x10
6
 cells in 6-well plates coated with 0.3 µg PLL and transfected at 141 
DIV4 with 50 nM siRNA using DharmaFECT 3 (Dharmacon) according to the manufacturerÕs instructions. Three 142 
days post-transfection, neurons were detached with 0.25% Trypsin and replated on a Nogo-A-20 or control 143 
substrate for 24 h as described above. Swiss 3T3 cells were plated at 2.9x10
4
 in 24-well plates and transfected 144 
with 50 nM siRNA using DharmaFECT 3 (Dharmacon) according to the manufacturerÕs instructions. 3 days post-145 
transfection, cells were replated on a Nogo-A-20 or control substrate for 1 h. Following siRNAs were used: rat 146 
Syndecan-3 ON-TARGETplus SMARTpool Sdc3 siRNA (L-098896-02-0005), mouse Glypican-1 ON-147 
TARGETplus SMARTpool Gpc1 siRNA (L-049268-01-0005), mouse Glypican-4 ON-TARGETplus 148 
SMARTpool Gpc4 siRNA (L-045841-01-0005), mouse Glypican-6 ON-TARGETplus SMARTpool Gpc6 siRNA 149 
(L-049420-01-0005) and ON-TARGETplus siRNA non-targeting pool (D-001810-10-0005) (Thermo Scientific, 150 
Dharmacon). Quantification of the respective mRNA knockdown was performed by qRT-PCR.  151 
 152 
The following Mission shRNA (Sigma) pLKO lentiviral plasmids containing shRNA against mouse Syndecan-4 153 
and non-target shRNA were used for the generation of Swiss 3T3 ctrl and Sdc4 shRNA stable cell lines: 154 
TRCN0000331554 and SHC202 (TRC2 vector). Lentiviral plasmids were transfected into HEK293T cells using 155 
PEI (polyethyleimine) 25 kDa (Polysciences Inc.). Lentiviruses were concentrated from filtered culture media 156 
 (0.45 µm) by ultracentrifugation at 25000 rpm for 2 h. Quantification of the respective mRNA knockdown was 157 
performed by qRT-PCR.  158 
 159 
Quantitative real-time PCR (qRT-PCR) 160 
Total RNA was isolated with the RNeasy Micro kit (Qiagen) and reverse-transcribed using TayMan Reverse 161 
Transcription Reagents (Applied Biosystems). cDNA was amplified using the Light Cycler 480 thermocycler 162 
(Roche) with the polymerase ready mix (SYBR Green I Master, Roche). Relative quantification was performed 163 
using the comparative CT method. cDNA levels were normalized to the reference genes Gapdh and Rpl19 (mouse) 164 
or Gapdh and eF1a1 (rat). Each reaction was done in triplicate. Melting curve analysis of PCR products followed 165 
by gel electrophoresis was performed to verify amplicons. Following primers were used: 166 
 167 
mouse Gapdh_FWD: 5Õ- CAGCAATGCATCCTGCACC -3Õ, 168 
mouse Gapdh_REV: 5Õ- TGGACTGTGGTCATGAGCCC -3Õ; 169 
mouse Rpl19_FWD: 5Õ- TGAGTATGCTCAGGCTACAG -3Õ, 170 
mouse Rpl19_REV: 5Õ- GAATGGACAGTCACAGGCTT -3Õ; 171 
mouse Sdc4_FWD: 5Õ- TTCTGGAGATCTGGATGACAC -3Õ, 172 
mouse Sdc4_REV: 5Õ- CACCAAGGGCTCAATCAC -3Õ; 173 
mouse Gpc1_FWD: 5Õ- ACTCCATGGTGCTCATCACTGAC -3Õ, 174 
mouse Gpc1_REV: 5Õ- TTCCACAGGCCTGGATGACCTTAG -3Õ; 175 
mouse Gpc4_FWD: 5Õ- ACCGACTGGTTACTGATGTCAAGG -3Õ, 176 
mouse Gpc4_REV: 5Õ- TTGCAAACGGTGCTTGGGAGAG -3Õ; 177 
mouse Gpc6_FWD: 5Õ- : GTCAGCAAAGGTCTTTCAGG -3Õ, 178 
mouse Gpc6_REV: 5Õ- GGTCTTTCCTCAGGGTTGTAG -3Õ; 179 
rat Gapdh_FWD: 5Õ- CTCTCTGCTCCTCCCTGTTC -3Õ, 180 
rat Gapdh_REV: 5Õ- GCCAAATCCGTTCACACC -3Õ; 181 
rat eF1฀1_FWD: 5Õ- GCCACCATACAGTCAGAAGAG -3Õ, 182 
rat eF1฀1_REV: 5Õ- GAACCACGGCATATTAGCAC -3Õ. 183 
rat Sdc3_FWD: 5Õ- TCCACGACAATGCCATCGACTC -3Õ, 184 
rat Sdc3_REV: 5Õ- ACCTACGATCACAGCTACGAGCAC -3Õ; 185 
 186 
ELISA 187 
The ELISA was modified according to method described in (Purushothaman et al., 2007). Biotinylated GAGs 188 
(0.5 µg per well) were immobilized onto a streptavidin-coated 384-well-plate (Pierce/Thermo scientific, IL, 189 
USA). Biotinylation of GAGs was performed by EDC and biotin-LC-hydrazide conjugation (Pierce/Thermo 190 
Scientific). After biotinylated GAGs were immobilized on the plates, the plates were blocked in 1% BSA and 191 
subjected to the binding of recombinant Nogo-66-Fc or Nogo-A-20. The bound Nogo variants were then 192 
recognized by the anti-T7, anti-Fc or 11C7 antibodies. The bound antibodies were detected using anti-mouse-193 
alkaline phosphatase conjugated antibodies followed by a direct measurement of absorbance at 405 nm using p-194 
nitrophenylphosphate (Sigma Aldrich). BSA only controls (no recombinant proteins) measurements were used as 195 
baseline in every experiment and subtracted from the other readings. For quantification, the mean ± SEM of 196 
absorbance measurements was determined from three experiments. 197 
 198 
Explant assay 199 
P5 explants were prepared from C57/BL6 pups according to (Wichterle et al., 1997). Tissues from the SVZ and 200 
RMS were embedded in 75% Matrigel growth factor reduced (BD Biosciences) and maintained for 1 day in 201 
Neurobasal medium (Invitrogen) supplemented with B27 (1x; Miltenyi), Pen/Strep (20 U/ml; Sigma), and 0.5 mM 202 
glutamine (Invitrogen). Antibodies and compounds were mixed with Matrigel: 11C7 (Oertle et al., 2003), 1 µg/µl; 203 
mouse anti-human IgG, 1 µg/µl (Jackson ImmunoResearch); HepIII, 500 mU/ml (Sigma); JTE-013, 250nM, 204 
500nM or 2µM (Tocris). Only vital explants with cells moving out of the tissue core in chains were analyzed. 205 
Explants were fixed in 4% PFA for 40, 1 µg/µl min and stained using 4Õ,6-diamidino-2-phenylindole (DAPI; 206 
Fluka) to visualize cell nuclei or labeled for฀III Tubulin or Doublecortin (Rolando et al., 2012) to mark 207 
neuroblasts. 208 
For adhesion experiments, adult SVZs were dissociated and SVZ-cells were either plated on poly-D-lysine (PDL) 209 
only or Nogo-AÐΔ20-coated coverslips (12,000 cells/cm
2
 in DMEM/F-12 supplemented with B27) (Rolando et 210 
al., 2012). Briefly, glass coverslips (1cm
2
) were first coated with PDL (5 µg/ml) and then with Nogo-AÐΔ20 211 
(100 pmol/cm
2
). Cells were pre-incubated with HepIII and/or 11c7 or with JTE-013 for 30 min and subsequently 212 
plated for 1 h. Cells were fixed, stained with DAPI and for III Tubulin and scored. The average number of 213 
adhered cells was determined by counting in five randomly chosen fields of view of the coverslips. 214 
215 
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